Erik A. A. Wallen

Erik A. A. Wallen

Auto-generated profile, based on publicly available information

Erik A. A. Wallen

Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014 Helsinki, Finland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
TSTina Seifert
Tina Seifert
MMMarcus Malo
Marcus Malo
TKTarja Kokkola
Tarja Kokkola
KEKarin Engen
Karin Engen
MFMaria Fridén-Saxin
Maria Fridén-Saxin
KLKristina Luthman
Kristina Luthman
Sirtuins (SIRTs) catalyze the NAD+-dependent deacetylation of Nε-acetyl lysines on various protein substrates. SIRTs are interesting drug targets as they are considered to be related to important pathologies such as inflammation and aging-associated diseases. We have previously shown that chroman-4-ones act as potent and selective inhibitors of SIRT2. Herein we report novel chroman-4-one and chromone-based SIRT2 inhibitors containing various heterofunctionalities to improve pharmacokinetic properties. The compounds retained both high SIRT2 selectivity and potent inhibitory activity. Two compounds were tested for their antiproliferative effects in breast cancer (MCF-7) and lung carcinoma (A549) cell lines. Both compounds showed antiproliferative effects correlating with their SIRT2 inhibition potency. They also increased the acetylation level of α-tubulin, indicating that SIRT2 is likely to be the target in cancer cells. A binding mode of the inhibitors that is consistent with the SAR data was proposed based on a homology model of SIRT2.

22 July 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
THTero Huhtiniemi
Tero Huhtiniemi
TSTiina Suuronen
Tiina Suuronen
VRValtteri M. Rinne
Valtteri M. Rinne
CWCarsten Wittekindt
Carsten Wittekindt
MLMaija Lahtela-Kakkonen
Maija Lahtela-Kakkonen
JLJukka Leppänen
Jukka Leppänen

1 October 2004 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EJElina M. Jarho
Elina M. Jarho
JVJarkko I. Venäläinen
Jarkko I. Venäläinen
JHJuhani Huuskonen
Juhani Huuskonen
JCJohannes A. M. Christiaans
Johannes A. M. Christiaans
JGJ.Arturo García-Horsman
J.Arturo García-Horsman
EWErik A. A. Wallén
Erik A. A. Wallén

1 February 2006 in Biochemical Pharmacology
Verified
Journal Article
Closed access
JVJarkko I. Venäläinen
Jarkko I. Venäläinen
JGJ.Arturo García-Horsman
J.Arturo García-Horsman
MFMarkus M. Forsberg
Markus M. Forsberg
AJAaro Jalkanen
Aaro Jalkanen
EWErik A.A. Wallén
Erik A.A. Wallén
PMPekka T. Männistö
Pekka T. Männistö

1 April 2011 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
CDChristine Dyrager
Christine Dyrager
MWMalin Wickström
Malin Wickström
MFMaria Fridén-Saxin
Maria Fridén-Saxin
AFAnnika Friberg
Annika Friberg
KDKristian Dahlén
Kristian Dahlén
KLKristina Luthman
Kristina Luthman

18 March 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PKPäivi H. Kiviranta
Päivi H. Kiviranta
TSTiina Suuronen
Tiina Suuronen
EWErik A. A. Wallén
Erik A. A. Wallén
JLJukka Leppänen
Jukka Leppänen
JTJussi Tervonen
Jussi Tervonen
EJElina M. Jarho
Elina M. Jarho